Cancers 2018, 10(3), 72; https://doi.org/10.3390/cancers10030072
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
Received: 3 February 2018 / Revised: 9 March 2018 / Accepted: 13 March 2018 / Published: 14 March 2018
(This article belongs to the Special Issue Immunohistochemistry and Cancer Diagnosis)
Abstract
Immunohistochemistry is a widely available technique that is less challenging and can provide clinically meaningful results quickly and cost-efficiently in comparison with other techniques. In addition, immunohistochemistry allows for the evaluation of cellular localization of proteins in the context of tumor structure. In an era of precision medicine, pathologists are required to classify lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted therapies. This review summarizes the hot topics of immunohistochemistry in lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine markers; (iii) ALK, ROS1, and EGFR; (iv) PD-L1 (CD274); (v) lung carcinoma vs malignant mesothelioma; and (vi) NUT carcinoma. Major pitfalls in evaluating immunohistochemical results are also described. View Full-TextKeywords:
immune checkpoint; immunostaining; INSM1; morphology; non-small cell lung carcinoma (NSCLC); pathology; thoracic tumor; small cell lung carcinoma (SCLC); tyrosine kinase; WHO classification
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Inamura, K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers 2018, 10, 72.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.